Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Immunology
Impact-faktor: 1.352 5-jähriger Impact-Faktor: 3.347 SJR: 1.022 SNIP: 0.55 CiteScore™: 2.19

ISSN Druckformat: 1040-8401
ISSN Online: 2162-6472

Volumen 39, 2019 Volumen 38, 2018 Volumen 37, 2017 Volumen 36, 2016 Volumen 35, 2015 Volumen 34, 2014 Volumen 33, 2013 Volumen 32, 2012 Volumen 31, 2011 Volumen 30, 2010 Volumen 29, 2009 Volumen 28, 2008 Volumen 27, 2007 Volumen 26, 2006 Volumen 25, 2005 Volumen 24, 2004 Volumen 23, 2003 Volumen 22, 2002 Volumen 21, 2001 Volumen 20, 2000 Volumen 19, 1999 Volumen 18, 1998 Volumen 17, 1997 Volumen 16, 1996 Volumen 15, 1995 Volumen 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v25.i2.20
pages 103-122

Platelet Activation and the CD40/CD40 Ligand Pathway: Mechanisms and Implications for Human Disease

Silvio Danese
Department of Internal Medicine, Catholic University of Rome, Rome, Italy
Claudio Fiocchi
Division of Gastroenterology, University Hospitals of Cleveland, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA


The discovery that platelets express CD40 and the CD40 ligand has transformed these cells, once seen as exclusively involved in coagulation and thrombosis, into active players of immunity and inflammatory injury. Many of the broad and potent biological activities mediated through the CD40/CD40 pathway by immune and nonimmune cells are also exerted by activated platelets. This occurs either through the constitutive expression of CD40 on the platelet surface or the activation-induced expression of the CD40 ligand, which is membrane bound and released from the surface in a soluble form. The most prominent activities mediated by the platelet CD40/CD40 ligand pathway include inflammatory, immunoregulatory, and hemostatic functions, all of which contribute to the newly expanded view of platelets as key biological mediators involved in disease processes such as atherosclerosis, inflammatory bowel disease, and diabetes. Therefore, considering platelet CD40 and CD40 ligand as novel biological targets is justified and supported by animal studies. The clinical profit to be gained from blocking this molecular pair will be determined by results in humans with conditions in which the platelet CD40/CD40 ligand pathway is crucially involved in disease pathogenesis.

Articles with similar content:

How Phagocytes Track Down and Respond to Apoptotic Cells
Critical Reviews™ in Immunology, Vol.29, 2009, issue 2
Philippe Frachet, Pascale Tacnet-Delorme, Gerard J. Arlaud, Helena Paidassi
Immunometabolic Signaling Pathways Contribute to Macrophage and Dendritic Cell Function
Critical Reviews™ in Immunology, Vol.36, 2016, issue 5
Aditya P. Dandekar, Lucas T. Jennelle, Tshifhiwa Magoro, Young S. Hahn
Clinical and Experimental Sepsis Impairs CD8 T-Cell-Mediated Immunity
Critical Reviews™ in Immunology, Vol.36, 2016, issue 1
Robert K. Strother, Derek B. Danahy, Thomas S. Griffith, Vladimir P. Badovinac
The Role of Plasmacytoid Dendritic Cell-Derived IFNα in Antiviral Immunity
Critical Reviews™ in Immunology, Vol.28, 2008, issue 1
Angela Dolganiuc, Gyongyi Szabo
A CCL2-Based Fusokine as a Novel Biopharmaceutical for the Treatment of CCR2-Driven Autoimmune Diseases
Critical Reviews™ in Immunology, Vol.30, 2010, issue 5
Jacques Galipeau, Moutih Rafei